

NEXEON

Adaptive bioelectronics solutions

Nexeon MedSystems is automating the nervous system to empower patients to be free

Nexeon Medsystems, Inc. is a global medical device company focused on providing innovative neurostimulation products that improve the quality of life of patients suffering from debilitating neurological disease. Nexeon has developed and commercialized a neurostimulation system that can be utilized to treat a variety of neurological diseases.

Best-in-class, adaptive bioelectronics systems creating novel solutions to engage and treat the nervous system

Trading symbol: OTC:QB NXNN

Focus: bioelectronics, medical technology

Proprietary platform: the Synapse™ system


Leading Product: Synapse™ deep brain stimulation for the treatment of the symptoms associated with Parkinson's disease

Revenues: \$7M trailing 12 months, longterm contracts with Fortune 500 companies

High barriers to entry: 100+ patents related to implantable medical devices and Internet of Medical Things technology, vertically-integrated manufacturing

Established DBS Sales Channel


After 20+ yrs proven efficacy (~135,000 DBS recipients worldwide)



Drastically underserved patient need in a market experiencing explosive growth.


Medtech companies have never had a better opportunity to be the connective tissue that binds the healthcare delivery system to the patient. As hospitals and clinicians seek to deliver more health services in the home instead of the hospital, medtech companies can be key to bridging distance, time, & boundaries between clinicians & patients.

The global bioelectronics market will pass \$7 billion by 2020




- SCS (Spinal cord stimulation)
- VNS (Vagus nerve stimulation)
- DBS (Deep brain stimulation)
- Others
- SNS (Sacral nerve stimulation)

Worldwide Landscape



Annual Sales In millions of USD



Market for DBS devices to treat patients with Parkinson's disease projected to reach


\$1.59B globally by 2020

Synapse Therapy Advantages

The Only System That Alleviates Shortcomings in Today's DBS Therapy



- ✓ **FASTER, PATIENT-SPECIFIC PROGRAMMING**
LFP recording, 16 controllable current sources with multiple stimulation frequencies, and delivery of most any conceivable waveform
- ✓ **ADAPTIVE SYSTEM**
Sensing & recording capabilities allow for improved monitoring of disease progression & therapy efficacy & provides foundation for closed-loop system
- ✓ **REMOTE MONITORING**
Increases patient independence while decreasing in-office visits with physician
- ✓ **RECHARGEABLE IMPLANT**
Diminishes need for future neurosurgeries



Key Events

- Q1 2018: OTC:QX Uplist
- Q2 2018: CE Mark Filed
- Q3 2018: Commercial Launch

Contact

Nexeon MedSystems Inc
1910 Pacific Avenue, Suite 20000, Dallas, TX 75201
Toll Free: 1-844-919-999, US Corp. HQ: +1-214-414-0454
info@nexeonmed.com
www.nexeonmed.com



Key information

Trading Symbol: NXNN
Shares Issued: 26,895,011
Options Outstanding: 3,752,000 (@\$1.00)
Warrants: 1,336,761 (@\$2.21 average price)
Fully Diluted Shares: 31,278,062
Float: 7,374,390
Market Cap: \$42M

Senior Executive Leadership



Will Rosellini, JD, MBA, MS - Chairman, Chief Executive Officer

6 advanced degrees related to translational medicine, 15-yr vet in neurotech, 3 successful exits in medtech

Brian Blischak - President, Chief Commercial Officer

Neuroengineer with 20 yrs in medical device field, Successfully led 3 neurostim product launches from new product to US approval



Daniel Powell - Vice President, Sales & Marketing

20 yrs in advanced medical technology products, including 12+ yrs in neuromodulation device & market development; most recently led global marketing for LivaNova's flagship \$315M VNS Epilepsy Therapy business

Forward Looking Statements

This information contains forward-looking statements which may be identified by their use of words like "plans," "expects," "will," "believes," "intends," "estimates," "anticipates" or other words of similar meaning. All statements that address expectations or projections about the future, including statements about Nexeon MedSystems Inc's ("Nexeon") growth strategy, product development, regulatory approval, market position, anticipated benefits of acquisitions, timing of anticipated benefits from restructuring actions, outcome of contingencies, such as litigation and environmental matters, expenditures and financial results, are forward-looking statements. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond the company's control. Some of the important factors that could cause the company's actual results to differ materially from those projected in any such forward-looking statements are: fluctuations in energy and raw material prices; failure to develop and market new products and optimally manage product life cycles; significant litigation and environmental matters; failure to appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; business or supply disruptions; security threats, such as acts of sabotage, terrorism or war, weather events and natural disasters; ability to protect and enforce the company's intellectual property rights; successful integration of acquired businesses and separation of under-performing or non-strategic assets or businesses. The company undertakes no duty to update any forward-looking statements as a result of future developments or new information.